– Results across NEURO-TTRansform subgroups show consistent benefit in neuropathy impairment and improved quality of life, regardless of patient segmentation – CARLSBAD, Calif., May 23, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will present new subgroup analyses from Ionis and AstraZeneca's Phase 3 NEURO-TTRansform study of WAINUA™ (eplontersen) at the 2024 International Symposium on Amyloidosis (ISA) in Rochester, Minnesota, May 26-30. WAINUA was approved by th ...

Shares of Ionis Pharmaceuticals (IONS) and Biogen (BIIB) lost at least 2% in market cap on Thursday after the companies announced their decision to terminate the development of their investigational amyotrophic lateral sclerosis (ALS) drug, BIIB105 / ION541. This decision was based on topline data from the phase I/II ALSpire study, wherein treatment with the drug did not slow disease progression. This was evident from the six-month data from the study wherein ALS patients treated with BIIB105 did not achiev ...

Part 1 of the HALOS trial was a three-month, multiple-ascending dose (MAD) study in 51 patients aged 2-50, which evaluated three doses of ION582. All eligible patients transitioned into the Part 2 long-term extension (LTE) portion of the study, which is evaluating the two higher doses of ION582 for an additional 12 months. Part 3 of the study will evaluate eligible patients for an additional three years. Topline results were available for all patients at four months (one month after last MAD dose), and six ...

CARLSBAD, Calif., May 15, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2024 virtual Annual Meeting of Stockholders followed by a general corporate update on Thursday, June 6, 2024. The agenda for the event is as follows: About Ionis Pharmaceuticals, Inc. For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has five marketed medicines and a leading pipeline in neurology, c ...

Ionis Pharmaceuticals (IONS) reported a loss of 98 cents per share for first-quarter 2024, which was narrower than the Zacks Consensus Estimate of a loss of $1.10 per share.The bottom line includes compensation expenses related to equity awards. Excluding these special items, adjusted loss per share was 77 cents against a loss of 68 cents per share in the year-ago quarter.Total revenues were $119 million in the first quarter, missing the Zacks Consensus Estimate of $131.5 million. Revenues declined 1.2% yea ...

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q1 2024 Results Conference Call May 7, 2024 11:30 AM ET Company Participants Wade Walke - SVP of IR Brett Monia - CEO Kyle Jenne - Chief Global Product Strategy Officer Beth Hougen - CFO Richard Geary - Chief Development Officer Eric Swayze - EVP of Research Eugene Schneider - Chief Clinical Development Officer Jonathan Birchall - Chief Commercial Officer Conference Call Participants Debjit Chattopadhyay - Guggenheim Securities Gary Nachman - Raymond James Jessica F ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission file number 000-19125 Ionis Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 33-0336973 (State or oth ...

CARLSBAD, Calif., May 7, 2024 – Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the "Company"), today reported financial results for the first quarter ended March 31, 2024. "Ionis is off to a great start in 2024, as we continue to execute on our vision to bring better futures to people with serious diseases. The WAINUA launch for hereditary ATTR polyneuropathy is progressing well with AstraZeneca. And we are one step closer to our first independent launch with our NDA submission for olezarsen, which is supporte ...

Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $0.98 per share versus the Zacks Consensus Estimate of a loss of $1.10. This compares to loss of $0.87 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 10.91%. A quarter ago, it was expected that this drug discovery and development company would post a loss of $0.78 per share when it actually produced a loss of $0.06, delivering a surprise of 92.31%.Over the last fo ...

Wall Street analysts expect Ionis Pharmaceuticals (IONS) to post quarterly loss of $1.10 per share in its upcoming report, which indicates a year-over-year decline of 26.4%. Revenues are expected to be $131.51 million, up 0.4% from the year-ago quarter.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 1.2% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Prior to a company's ea ...